Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.58 |
| ▸ | MTOR | P42345 | 20/20 | 0.58 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.55 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.46 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.44 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.44 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.44 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL55648 | 0.92 | PIK3CA (0.66) | PIK3CAMTORPIK3CBPIK3CGMAPK14 | |
| SCHEMBL56285 | 0.88 | PIK3CA (0.68) | PIK3CAMTORPIK3CBPIK3CGMAPK14 | |
| SCHEMBL55996 | 0.88 | PIK3CA (0.69) | PIK3CAMTORPIK3CBPIK3CGMAPK14 | |
| SCHEMBL56007 | 0.84 | PIK3CA (0.70) | PIK3CAMTORPIK3CBPIK3CGMAPK14 | |
| SCHEMBL61780 | 0.83 | PIK3CA (0.67) | PIK3CAMTORPIK3CBPIK3CGMAPK14 | |
| SCHEMBL55600 | 0.81 | PIK3CA (0.60) | PIK3CAMTORPIK3CB | |
| SCHEMBL55143 | 0.80 | PIK3CA (0.90) | PIK3CAMTORPIK3CB | |
| SCHEMBL55481 | 0.80 | PIK3CA (0.78) | PIK3CAMTORPIK3CB | |
| SCHEMBL60905 | 0.80 | PIK3CA (0.69) | PIK3CAMTORPIK3CBPIK3CGMAPK14 | |
| SCHEMBL53800 | 0.80 | PIK3CA (0.77) | PIK3CAMTORPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129371-B2 | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors | WYETH LLC (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2212333-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | Wyeth LLC (US) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009052145-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | MTOR, PIK3CA, PIK3CD | PIK3CA 2/4885MTOR 1/4885PIK3CB 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.